Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of serum protein levels as potential biomarkers to predict clinical benefit in advanced non-small cell lung cancer patients treated with nivolumab

Trial Profile

Evaluation of serum protein levels as potential biomarkers to predict clinical benefit in advanced non-small cell lung cancer patients treated with nivolumab

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 20 Apr 2018 New trial record
    • 18 Apr 2018 Results presented at the 109th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top